Why contract drug manufacturers meet FDA norms easily while others struggle
Contract development and manufacturing organisations undergo several rounds of inspections before they are engaged by client companies to make key drug ingredients.
Know your stock | Why are analysts upbeat on KIMS?
General Atlantic Singapore sold a 2.89 percent stake in KIMS in a block deal on May 30 for Rs 371.3 crore, grabbing an opportunity offered by a surge in the share price to book a partial profit
Apollo Hospitals' occupancy to reach 70%, Apollo 24*7 on path to breakeven: MD
Apollo Hospitals will reach its occupancy target by reducing its reliance on institutional patients and increasing focus on international patients, recruitment of more doctors and improving the payor mix.
Why are brokerages divided over Torrent Pharma’s outlook despite a strong Q4 show?
Many brokerages see margin pressure and expensive valuations impacting the stock while some others are betting on branded business and a steady domestic market to provide a boost.
Mazagon Dock Shipbuilders surges 5% on robust quarterly show
Mazagon Dock Shipbuilders also recorded its highest ever revenue and net profit for FY23.
Apollo Hospitals gains 2% on hopes of strong Q4 earnings
Apollo Hospitals' growth in the fourth-quarter is likely to be aided by a favourable base, strong seasonality and better occupancy.
Sun Pharma Preview: Strong specialty biz, robust domestic sales to boost company’s health in Q4
The company's specialty business is likely to post double-digit growth YoY in the quarter, despite some sequential moderation, according to brokerages.
Fed officials divided over support for more rate hikes, FOMC meet minutes show
While Fed officials were leaning towards a pause in rate hikes after the May meeting, an end to policy tightening still remains out of question.
Gland Pharma’s prospects after dismal earnings fail to impress investors
Analysts are also concerned about the lack of optimism in the management's commentary on margins improving.
Is dual drug filing the right tactic for pharma companies now?
While only two large-cap players have firmed up plans to embark on this route, analysts expect other players too to follow suit, albeit majorly for key drugs, thanks to the gains involved in simultaneously filing for new launches from two sites.
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
Divi's Laboratories is likely to report a slump in its Q4 earnings on a year-on-year basis. However, sequentially, the drugmaker may see some modest recovery in its financials.
Delayed drug launches to hurt Cipla’s earnings in FY24
An update by Cipla's management that key drug launches will now be delayed by around 12 months have prompted a slew of earnings downgrades for FY24.
Expect EBITDA margin to sustain at 25-30% in FY24, says Meghmani Finechem CMD Maulik Patel
Though the China+1 theme has lent greater focus on Indian manufacturing, Patel feels India has quite a distance to cover to catch up with China in this sphere.
Cipla's Q4 net profit surges 45% on year to Rs 525.65 crore, lags estimate
Cipla's Q4 revenue was largely in-line with the Street's expectations of Rs 5,744.42 crore.
Closing Bell: Sensex up 123 points, Nifty above 18,330; M&M, IndusInd, Axis Bank top gainers
Closing Bell: Nifty Bank, Auto shines; Metal, Oil & Gas, Pharma falls
Cipla Q4 preview: Robust domestic traction, gRevlimid sales likely to give earnings a big boost
Cipla Q4 preview: The company is expected to double its consolidated net profit to Rs 723.4 crore from Rs 362.07 crore in the year-ago quarter. It is also seen as the biggest beneficiary of a strong flu season in India
Dr Reddy's fall 5% even after Q4 net profit jumps 10-fold. Here's why
Despite the huge jump, Dr Reddy's net profit for the fourth quarter lagged Street's estimate and brokerages are concerned about the firm's growth map
Closing Bell: Indices close marginally lower; Dr Reddy's, L&T, Hindalco, Divi's Lab top losers
Closing bell: Sensex, Nifty close marginally lower. Dr Reddy's, L&T, Hindalco, Divi's Lab top losers while Adani Ent, Asian Paints, HUL top gainers
Dr Reddy's Q4 net profit jumps to Rs 959 crore on favourable base, US launches, brand deals
Dr Reddy's bottomline also lagged the Street's estimate of Rs 1,093.6 crore.
Closing Bell: Sensex up 179 points, Nifty above 18,300; IndusInd, PowerGrid, Tata Motors top gainers
Closing Bell: Nifty Realty, Oil & Gas and Auto were the top sectoral gainers
US sales, brand deals to seal the fortune for Dr Reddy's in Q4
Dr Reddy's is poised to reap the benefits of brand sales of Rs 275 crore, which will incrementally boost its headline numbers for Q4.
Closing Bell: Indices close flat, Nifty near 18,250; ITC, SBI, Bajaj Finance worst hit
Closing Bell: Nifty IT, Pharma, Auto shine, PSU Banks, Realty worst hit.
One-time loss, weak operational performance drags UPL Q4 earnings below street expectations
The company also missed the target to reduce its net debt by $500 million during FY22-23. Going ahead, UPL has guided a revenue growth of 6-10 percent and an EBIDTA growth of 8-12 percent.
UPL shares trade marginally higher on hopes of robust Q4 earnings
According to ShareKhan by BNP Paribas, UPL is likely to defy industry trends during Q4 and exhibit a better performance due to its global market exposure and the advantage of backward integration.
- Need To Take Measures Against Terror Financing And Propaganda: Jaishankar At BRICS Meeting Watch more
- Apple WWDC 2023: What To Expect At Apple’s Big Event? Watch more
- Growth Of Indian Luxury Market: Why Are Global Brands Bullish On Indian Ambassadors? Watch more
- ITC Vs HUL: How Do The FMCG Majors Fare Post Their Q4 Numbers? Watch more
- India Focussed On Improving Business Viability: Morgan Stanley MD Ridham Desai's Praises PM Modi Watch more